GenSpera and the Statewide Clinical Trials Network of Texas to Conduct Phase II Study of G-202 in Patients With Hepatocellular Carcinoma

SAN ANTONIO, Texas--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB:GNSZ) announced that its lead drug, G-202, has been selected by the Statewide Clinical Trials Network of Texas (CTNeT) for evaluation in a Phase II clinical trial in patients with hepatocellular carcinoma (HCC). CTNeT’s selection of G-202 is the result of a competitive, peer-review process to identify promising molecularly-targeted agents with likelihood of clinical benefit and rapidly move them into the Phase II setting. The clinical trial, entitled “A Phase II, Multicenter, Single-Arm Study of G-202 as Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma” is the first clinical trial launched by CTNeT, an organization founded by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and focused on moving targeted therapies and clinical research forward at an accelerated pace.

Back to news